Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On March 6, 2024, the grand conference on optimizing the business environment and promoting high-quality economic development was held in Wu Zhong Economic Development Zone (EDZ). Ding Lixin, Secretary of the District Committee and Party Working Committee of EDZ, Gu Xiaodong, Deputy Secretary of the District Committee and District Governor, Fang Weijun, Director of the Standing Committee of the District People's Congress, Xu Zhenhua, Chairman of the District Political Consultative Conference, and other government leaders attended the meeting. Mr. Zhao Hai, Chairman of Olipharma, was invited to attend the conference.
The conference collectively conducted an in-depth study of General Secretary Xi Jinping's important expositions on optimizing the business environment, as well as his key speeches and instructions regarding work in Jiangsu and Suzhou. Meanwhile, Wu Zhong Economic Development Zone awarded multiple honorary prizes, including Outstanding Tax Contribution Enterprises, Industry Leading Enterprises, Excellent Open Enterprises, and Advanced Science and Technology Innovation Enterprises.Olipharma Honored with the "Advanced Enterprise in Scientific and Technological Innovation" Award by Wuzhong Economic Development Zone
Olipharma Honored with the "2023 Annual Science and Technology Innovation Advanced Enterprise" AwardSuzhou Olipharma Technology Co., Ltd. is a professional pharmaceutical nucleic acid CRDMO company that provides customers with "one-stop" services ranging from nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, to drug registration. The technical team of Olipharma comes from one of the earliest groups in China to engage in the development of nucleic acid drug manufacturing processes and CMC research, possessing extensive experience in project development and product registration. Currently, the company has established four industry-leading core technology platforms: nucleic acid solid-phase synthesis, chemical modification and conjugation, process development and analysis, as well as CMC pharmaceutical research. It has also initiated in-depth collaborations with multiple pharmaceutical companies and biotechnology firms both domestically and internationally.
